Gastrointestinal Stromal Tumors: Molecular Mechanisms and Targeted Therapies
Author Information
Author(s): Erinn Downs-Kelly, Brian P. Rubin
Primary Institution: Cleveland Clinic
Hypothesis
The review explores the molecular mechanisms and treatment options for gastrointestinal stromal tumors (GISTs), particularly focusing on KIT and PDGFRA mutations.
Conclusion
GISTs are driven by oncogenic KIT or PDGFRA mutations, and while they initially respond to imatinib, resistance to this and other treatments is a significant challenge.
Supporting Evidence
- 85-90% of GISTs have mutations in KIT or PDGFRA.
- Imatinib has shown clinical responses in up to 80% of GIST cases.
- GISTs can occur anywhere in the gastrointestinal tract, with the stomach and small bowel being the most common sites.
- Secondary mutations can lead to resistance against imatinib treatment.
Takeaway
GISTs are tumors in the stomach and intestines that can be treated with special medicines, but sometimes they stop working, and doctors need to find new ways to help.
Methodology
This is a review article summarizing the molecular mechanisms, clinical features, and treatment options for GISTs.
Limitations
The review does not provide new experimental data but summarizes existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website